Dapivirine vs Doravirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Dapivirine · Dapivirine Vaginal Ring
Marketed by Population Council and partners
NCT01617096 · Phase 3 · completed
This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with participants and investigators blinded, and used HIV-1 seroconversion as the primary endpoint. The published analysis shows a 27% lower incidence of HIV-1 infection with dapivirine (95% CI 1 to 46; P = 0.046). The design is robust and the primary comparison is statistically significant, although the effect was smaller where adherence was low.
Reported efficacy
Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. (minimum of 12 months and a maximum of 14 months per participant); The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). (minimum of 12 months and a maximum of 14 months per participant): HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). (met)
Result source: NCT01617096
Doravirine · Pifeltro
Marketed by Merck & Co.
NCT02275780 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)
Result source: NCT02403674
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Dapivirine | Doravirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT06250504 | 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757803 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06250504 | 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778 |
| CD4 count, change (week 48) | —Trial running · NCT06250504 | 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578014 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Doravirine
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
3 other results
- 84.3% vs 80.8% NCT02403674
- 73.1% vs 66% NCT02275780
- 77.5% vs 73.6% NCT02403674
HIV-1 RNA 50 copies/mL or more (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Doravirine
- 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778
CD4 count, change (week 48)
- Dapivirine
- —Trial running · NCT06250504
- Doravirine
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
14 other results
- 192.7 vs 185.6 NCT02275780
- 217.1 vs 319.9 NCT04233879
- 182.4 vs 233.5 NCT04233879
- 0.5 vs 66.3 NCT04223791
- 5.4 vs 62.7 NCT04223791
- -19.7 vs 40.5 NCT04223791
- 239.6 vs 350.9 NCT04233879
- 259.2 vs 263.6 NCT01632345
- 191.9 vs 194.5 NCT01632345
- 133.6 vs 121.1 NCT01632345
- 152.3 vs 146 NCT01632345
- 140.7 vs 121.1 NCT01632345
- 112.9 vs 121.1 NCT01632345
- 154.1 vs 121.1 NCT01632345
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dapivirine: 4 of 4 rows · Doravirine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dapivirine | Doravirine |
|---|---|---|
| Dropout rate | 11.3%25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results9.9%25 mg NCT02862171 · Phase 3 3.6%25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence — NCT03593655 · Phase 2 · registry result, not featured evidence 5.5% NCT02028338 · Phase 2 · registry result, not featured evidence 2.8% NCT02010593 · Phase 2 · registry result, not featured evidence 20.9%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 23.3%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence 10.5% NCT03239483 · Phase 1 · registry result, not featured evidence 31% NCT01539226 · Phase na · registry result, not featured evidence | 24.2%100 mgb NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 19.6%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 10%Cohort 1: DOR NCT03332095 · Phase 1/2 2.2%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 20.4%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 8.2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 0% NCT04689737 · Phase 4 · registry result, not featured evidence 30.4%DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 80.2%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 17%Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 42.9%DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 33.3%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 43.6%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 28.6% NCT04900974 · Phase 1 · registry result, not featured evidence 0% NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results—25 mg NCT02862171 · Phase 3 —25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence — NCT03593655 · Phase 2 · registry result, not featured evidence — NCT02028338 · Phase 2 · registry result, not featured evidence — NCT02010593 · Phase 2 · registry result, not featured evidence 4.7%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence — NCT03239483 · Phase 1 · registry result, not featured evidence 0% NCT01539226 · Phase na · registry result, not featured evidence | 1.6%100 mgb NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 3%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 —Cohort 1: DOR NCT03332095 · Phase 1/2 —Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination — NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence — NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination —200 mg NCT01466985 · Phase 1 · registry result, not featured evidence —25 mg NCT01466985 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 8.8%25 mg DVR inserted once every 4 weeksa NCT01617096 · Phase 3 · monotherapy show 9 more results2.1%25 mg NCT02862171 · Phase 3 1.4%25 mg vaginal matrix ring NCT02858037 · Phase 3 · registry result, not featured evidence 0% NCT03593655 · Phase 2 · registry result, not featured evidence 2.7% NCT02028338 · Phase 2 · registry result, not featured evidence 1.4% NCT02010593 · Phase 2 · registry result, not featured evidence 2.3%Dapivirine Gel 4759 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0%Dapivirine Gel 4789 NCT00799058 · Phase 1/2 · registry result, not featured evidence 0% NCT03239483 · Phase 1 · registry result, not featured evidence 3.1% NCT01539226 · Phase na · registry result, not featured evidence | 11.7%100 mgb NCT02275780 · Phase 3 · combination show 44 more results6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 6%DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 4.5%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 5.2%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 6.3%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 8.2%DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 —MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 0%Cohort 1: DOR NCT03332095 · Phase 1/2 4.4%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 10.6%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 25% NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 4.3%DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 6.2%DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.6%DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1.5%DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 6.4%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 5.3%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.1%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 0%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.7%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.8%Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence 4%Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence 3.7%Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 2.7%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 10.2%100 mg NCT01632345 · Phase 2 · registry result, not featured evidence 7.3%200 mg NCT01632345 · Phase 2 · registry result, not featured evidence 2.3%50 mg NCT01632345 · Phase 2 · registry result, not featured evidence 10%25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 0% NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 25 mg DVR inserted once every 4 weeksa metrorrhagia 55.1% (placebo 55.6%) genitourinary chlamydia infection 20.5% (placebo 20.8%) menorrhagia 19.7% (placebo 18.4%) NCT01617096 · Phase 3 · monotherapy show 9 more results25 mg vaginal matrix ring genitourinary chlamydia infection 8.4% vaginal discharge 8% vulvovaginitis trichomonal 5.9% NCT02858037 · Phase 3 · registry result, not featured evidence any event in soc 58.5% any event in soc 32.4% creatinine renal clearance decreased 30.3% NCT03593655 · Phase 2 · registry result, not featured evidence metrorrhagia 20.5% (placebo 26.1%) vaginal discharge 15.1% (placebo 34.8%) bacterial vaginosis 12.3% (placebo 8.7%) NCT02028338 · Phase 2 · registry result, not featured evidence vaginal discharge 11.1% (placebo 12.5%) upper respiratory tract infection 8.3% (placebo 12.5%) vaginal odour 6.9% (placebo 0%) NCT02010593 · Phase 2 · registry result, not featured evidence vaginitis bacterial 16.3% (placebo 11.9%) vaginal candidiasis 9.3% (placebo 0%) abdominal pain lower 4.7% (placebo 0%) NCT00799058 · Phase 1/2 · registry result, not featured evidence vaginitis bacterial 34.9% (placebo 11.9%) vulvovaginal pruritus 9.3% (placebo 4.8%) headache 7% (placebo 7.1%) NCT00799058 · Phase 1/2 · registry result, not featured evidence diarrhoea 11.1% (placebo 22.2%) insomnia 11.1% (placebo 0%) anal pruritus 5.6% (placebo 0%) NCT03239483 · Phase 1 · registry result, not featured evidence gynaecological chlamydia infection 32.7% (placebo 32.7%) metrorrhagia 27% (placebo 29.6%) genital infection female 23% (placebo 19.3%) NCT01539226 · Phase na · registry result, not featured evidence | 100 mgb diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · combination show 33 more resultsnasopharyngitis 13.7% upper respiratory tract infection 7.2% headache 6.2% NCT02403674 · Phase 3 · HIV · phase 3 nasopharyngitis 9.7% upper respiratory tract infection 7.1% diarrhoea 6.3% NCT02403674 · Phase 3 · HIV · phase 3 aspartate aminotransferase increased 22.2% blood alkaline phosphatase increased 11.1% blood glucose increased 11.1% NCT03332095 · Phase 1/2 glomerular filtration rate decreased 55.6% alanine aminotransferase increased 46.7% blood creatinine increased 46.7% NCT03332095 · Phase 1/2 · combination 100 mg creatinine renal clearance decreased 10.6% low density lipoprotein increased 6.4% abdominal pain upper 2.1% NCT04636437 · Phase 4 · registry result, not featured evidence · combination 100 mg creatinine renal clearance decreased 8.2% aspartate aminotransferase increased 4.1% alanine aminotransferase increased 2% NCT04636437 · Phase 4 · registry result, not featured evidence · combination headache 8.1% covid-19 5.9% arthralgia 5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 13.1% lymphocyte count decreased 10.5% cd4 lymphocytes decreased 9.2% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 32.3% cd4 lymphocytes decreased 23.7% covid-19 12.4% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 15.9% cd4 lymphocytes decreased 11.4% covid-19 1.5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 2.6% nasopharyngitis 2% diarrhoea 1% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 100 mg/0.75 mg covid-19 14.1% headache 10.4% lymphocyte count decreased 9.1% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 24.1% cd4 lymphocytes decreased 10.5% covid-19 7.5% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 17.1% cd4 lymphocytes decreased 8.2% upper respiratory tract infection 2.7% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 14.3% accidental overdose 0% arthralgia 0% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg upper respiratory tract infection 6.3% insomnia 1.8% headache 0.9% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 headache 10.7% accidental overdose 7.1% covid-19 5.4% NCT04223778 · Phase 3 · registry result, not featured evidence lymphocyte count decreased 20.2% cd4 lymphocytes decreased 14% covid-19 13% NCT04223778 · Phase 3 · registry result, not featured evidence covid-19 17.5% lymphocyte count decreased 13.5% cd4 lymphocytes decreased 12% NCT04223778 · Phase 3 · registry result, not featured evidence blood creatine phosphokinase increased 28.6% (placebo 14.3%) diarrhoea 28.6% (placebo 14.3%) anaemia 14.3% (placebo 0%) NCT04233216 · Phase 3 · registry result, not featured evidence · combination dizziness 33.3% dyspepsia 33.3% headache 33.3% NCT04295772 · Phase 2 · registry result, not featured evidence covid-19 100% adjustment disorder 0% back pain 0% NCT04295772 · Phase 2 · registry result, not featured evidence oropharyngeal pain 10.8% cough 8.1% nasal congestion 8.1% NCT04295772 · Phase 2 · registry result, not featured evidence cough 28.6% oropharyngeal pain 21.4% rhinorrhoea 21.4% NCT04295772 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 17.6% diarrhea 14.8% dizziness 14.8% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 29.3% nausea 22% headache 17.1% NCT01632345 · Phase 2 · registry result, not featured evidence 50 mg abnormal dreams 20.9% nausea 16.3% headache 14% NCT01632345 · Phase 2 · registry result, not featured evidence 25 mg diarrhea 25% fatigue 17.5% influenza 15% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 33.3% (placebo 0%) headache 33.3% (placebo 33.3%) abdominal pain 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence 25 mg alanine aminotransferase increased 16.7% (placebo 0%) aspartate aminotransferase increased 16.7% (placebo 0%) decreased appetite 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapivirine
Doravirine
show 3 more results
show 14 more results
show 3 more results
show 3 more results
+ 43 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapivirine's landscape · Doravirine's landscape